This company has been marked as potentially delisted and may not be actively trading. Innovate Biopharmaceuticals (INNT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock INNT vs. PLRZ, SCPS, EVLO, ARDS, STAB, AMPE, CALA, CMRA, CLVR, and EFTRShould you be buying Innovate Biopharmaceuticals stock or one of its competitors? The main competitors of Innovate Biopharmaceuticals include Polyrizon (PLRZ), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), Comera Life Sciences (CMRA), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "medical" sector. Innovate Biopharmaceuticals vs. Polyrizon Scopus BioPharma Evelo Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Calithera Biosciences Comera Life Sciences Clever Leaves eFFECTOR Therapeutics Polyrizon (NASDAQ:PLRZ) and Innovate Biopharmaceuticals (NASDAQ:INNT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do insiders and institutionals believe in PLRZ or INNT? 5.9% of Innovate Biopharmaceuticals shares are owned by institutional investors. 7.9% of Innovate Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer PLRZ or INNT? In the previous week, Polyrizon had 4 more articles in the media than Innovate Biopharmaceuticals. MarketBeat recorded 4 mentions for Polyrizon and 0 mentions for Innovate Biopharmaceuticals. Polyrizon's average media sentiment score of 0.91 beat Innovate Biopharmaceuticals' score of 0.00 indicating that Polyrizon is being referred to more favorably in the media. Company Overall Sentiment Polyrizon Positive Innovate Biopharmaceuticals Neutral Which has higher earnings & valuation, PLRZ or INNT? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyrizonN/AN/AN/AN/AN/AInnovate BiopharmaceuticalsN/AN/A-$27.05MN/AN/A Is PLRZ or INNT more profitable? Company Net Margins Return on Equity Return on Assets PolyrizonN/A N/A N/A Innovate Biopharmaceuticals N/A N/A -234.42% Does the MarketBeat Community prefer PLRZ or INNT? Innovate Biopharmaceuticals received 203 more outperform votes than Polyrizon when rated by MarketBeat users. CompanyUnderperformOutperformPolyrizonN/AN/AInnovate BiopharmaceuticalsOutperform Votes20365.48% Underperform Votes10734.52% SummaryPolyrizon and Innovate Biopharmaceuticals tied by winning 3 of the 6 factors compared between the two stocks. Get Innovate Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INNT vs. The Competition Export to ExcelMetricInnovate BiopharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$8,000.00$6.47B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E Ratio-1.798.4026.7219.60Price / SalesN/A258.84395.56117.96Price / CashN/A65.8538.3234.62Price / BookN/A6.416.764.50Net Income-$27.05M$143.73M$3.23B$248.40M Innovate Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A$8,000.00N/A-1.798PLRZPolyrizonN/A$0.01-16.7%N/AN/A$23,000.00N/A0.00N/ANews CoveragePositive NewsGap UpHigh Trading VolumeSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00+66.7%N/AN/A$9,000.00N/A0.00120Gap DownHigh Trading VolumeARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.7%$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00+3.3%N/A-98.8%$4,000.00N/A0.0020Gap UpCALACalithera BiosciencesN/A$0.00flatN/A-97.0%$3,000.00N/A0.0060CMRAComera Life SciencesN/AN/AN/AN/A$3,000.00$1.00M0.002CLVRClever LeavesN/A$0.00flatN/A-100.0%$1,000.00$17.42M0.00560EFTReFFECTOR TherapeuticsN/A$0.00-66.7%N/A-100.0%$1,000.00$3.55M0.0010Upcoming Earnings Related Companies and Tools Related Companies PLRZ Competitors SCPS Competitors EVLO Competitors ARDS Competitors STAB Competitors AMPE Competitors CALA Competitors CMRA Competitors CLVR Competitors EFTR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INNT) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovate Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INNT Stock Free INNT Stock Alerts